• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Distinctive size effects of Pt nanoparticles immobilized on Fe3O4@PPy used as an efficient recyclable catalyst for benzylic alcohol aerobic oxidation and hydrogenation reduction of nitroaromatics
  Yu Long,Bing Yuan,Jianrui Niu,Xin Tong,Jiantai Ma New J. Chem., 2015,39, 1179-1185
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpene lactones
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Terpene lactones Diterpene lactones
• Diterpenoids
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Introduction to Ginkgolide A (CAS No. 15291-75-5)

Ginkgolide A, a naturally occurring compound with the chemical formula C??H??O??, is widely recognized for its significant pharmacological properties. This compound is primarily derived from the Ginkgo biloba tree, a species renowned for its medicinal applications in traditional and modern medicine. The CAS number 15291-75-5 uniquely identifies Ginkgolide A in scientific and industrial contexts, facilitating its accurate classification and research utilization.

The structural complexity of Ginkgolide A, characterized by its lactone ring and multiple hydroxyl groups, contributes to its diverse biological activities. Over the years, extensive research has been conducted to elucidate its mechanisms of action and therapeutic potential. One of the most notable findings is its ability to inhibit platelet-activating factor (PAF), a key mediator in various inflammatory and immune responses. This inhibitory effect has garnered significant attention in the field of cardiovascular and neurodegenerative diseases.

Recent studies have highlighted the therapeutic implications of Ginkgolide A in neuroprotection. Research indicates that it may help mitigate oxidative stress and inflammation, which are pivotal factors in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. The compound's ability to cross the blood-brain barrier further enhances its potential as a therapeutic agent for central nervous system disorders. These findings have spurred interest in developing Ginkgolide A-based drugs for treating cognitive decline and memory loss.

In addition to its neuroprotective properties, Ginkgolide A has shown promise in cardiovascular health. Studies suggest that it can improve blood circulation by dilating blood vessels and reducing platelet aggregation. This makes it a candidate for managing conditions such as angina pectoris and peripheral artery disease. The compound's anti-inflammatory effects also contribute to its potential role in preventing atherosclerosis, a major risk factor for heart disease.

The pharmacokinetics of Ginkgolide A have been extensively studied to optimize its delivery and efficacy. Research has demonstrated that oral administration can yield significant bioavailability, although the compound's rapid metabolism necessitates careful dosing strategies. Advances in drug delivery systems, such as nanoparticle formulations, have shown promise in enhancing the stability and bioavailability of Ginkgolide A, thereby improving therapeutic outcomes.

The safety profile of Ginkgolide A has been thoroughly evaluated through preclinical and clinical trials. These studies have consistently shown that the compound is well-tolerated at therapeutic doses, with minimal side effects reported. However, as with any pharmacological agent, careful monitoring is essential to ensure patient safety. Future research aims to explore synergistic combinations with other drugs to enhance therapeutic efficacy while minimizing adverse effects.

The industrial production of Ginkgolide A has evolved significantly over the years, with advancements in extraction and synthesis techniques. Modern methodologies leverage biotechnological approaches to produce high-purity compounds efficiently. These innovations have not only improved the availability of Ginkgolide A but also reduced costs, making it more accessible for research and commercial applications.

The future prospects of Ginkgolide A are promising, with ongoing research exploring new therapeutic applications. Emerging evidence suggests potential benefits in treating metabolic disorders, such as diabetes and obesity, by modulating lipid metabolism and insulin sensitivity. Additionally, its anti-aging properties are being investigated in-depth, with preliminary results indicating that Ginkgolide A may help delay age-related physiological decline.

In conclusion, Ginkgolide A (CAS No. 15291-75-5) is a multifaceted compound with significant therapeutic potential across various medical domains. Its ability to modulate inflammatory pathways, protect against neurodegenerative diseases, enhance cardiovascular health, and exhibit anti-aging effects positions it as a valuable candidate for future pharmaceutical development. As research continues to uncover new applications and optimize delivery methods, Ginkgolide A is poised to play an increasingly important role in modern medicine.

• 15291-76-6(Ginkgolide C)
• 115783-48-7(1,5-dioxo-2-oxa-3(S),9(R)-diacetyl-4(R),8(R)-dimethylhexahydroindane)
• 107438-79-9(Ginkgolide J)
• 15291-78-8(9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4H)-trione,3-(1,1-dimethylethyl)hexahydro-2,4,11-trihydroxy-8-methyl-, (1S,2R,3S,3aS,4R,6aR,7aR,7bR,8S,10aS,11R,11aS)-)
• 119878-93-2(1,4-(Epoxymethano)-1H-cyclopenta[c]furan-7-one,3,5-bis(acetyloxy)hexahydro-4-hydroxy-6-[(1R,3aS,7aR)-octahydro-4,4,7a-trimethyl-1H-inden-1-yl]-,(1S,3S,3aS,4R,5S,6R,6aS)-rel- (9CI))
• 135446-84-3(Chromodorolide B)
• 502421-87-6(7-epi-ginkgolide C)
• 33570-04-6(Bilobalide)
• 105268-96-0(Bn 52063)
• 15291-77-7(Ginkgolide B)